Evans Elizabeth S, Kocak Zafer, Zhou Su-Min, Kahn Daniel A, Huang Hong, Hollis Donna R, Light Kim L, Anscher Mitchell S, Marks Lawrence B
Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710, USA.
Cytokine. 2006 Aug;35(3-4):186-92. doi: 10.1016/j.cyto.2006.07.021. Epub 2006 Sep 18.
The purpose of the study was to reassess the utility of transforming growth factor-beta-1 (TGF-beta1) together with dosimetric and tumor parameters as a predictor for radiation pneumonitis (RP). Of the 121 patients studied, 32 (26.4%) developed grade > or =1 RP, and 27 (22.3%) developed grade > or =2 RP. For the endpoint of grade > or =1 RP, those with V30>30% and an end-RT/baseline TGF-beta1 ratio> or =1 had a significantly higher incidence of RP than did those with V30>30% and an end-RT/baseline TGF-beta1 ratio<1. For most other patient groups, there were no clear associations between TGF-beta1 values and rates of RP. These findings suggest that TGF-beta1 is generally not predictive for RP except for the group of patients with a high V30.
本研究的目的是重新评估转化生长因子-β1(TGF-β1)联合剂量学和肿瘤参数作为放射性肺炎(RP)预测指标的效用。在121例研究患者中,32例(26.4%)发生≥1级RP,27例(22.3%)发生≥2级RP。对于≥1级RP这一终点,V30>30%且放疗结束时/基线TGF-β1比值≥1的患者RP发生率显著高于V30>30%且放疗结束时/基线TGF-β1比值<1的患者。对于大多数其他患者组,TGF-β1值与RP发生率之间没有明确关联。这些发现表明,除了V30较高的患者组外,TGF-β1一般不能预测RP。